Journal article
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
The Journal of nuclear medicine (1978), Vol.59(1), pp.66-74
01/2018
DOI: 10.2967/jnumed.117.202275
PMCID: PMC6910630
PMID: 29025982
Abstract
Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should replace 111 In-pentetreotide scintigraphy (OctreoScan; Mallinckrodt) in all indications in which the latter is currently being used. These appropriate use criteria (AUC) are intended to aid referring medical practitioners in the appropriate use of SSTR PET for imaging of patients with NETs. The indications were evaluated in well-differentiated NETs. Of the 12 clinical scenarios evaluated, 9 were graded as appropriate: initial staging after the histologic diagnosis of NET, evaluation of an unknown primary, evaluation of a mass suggestive of NET not amenable to endoscopic or percutaneous biopsy, staging of NET before planned surgery, monitoring of NET seen predominantly on SSTR PET, evaluation of patients with biochemical evidence and symptoms of a NET, evaluation of patients with biochemical evidence of a NET without evidence on CI or a prior histologic diagnosis, restaging at time of clinical or laboratory progression without progression on CI, and new indeterminate lesion on CI with unclear progression. Representatives from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the American College of Radiology (ACR), the American Society of Clinical Oncology (ASCO), the North American Neuroendocrine Tumor Society (NANETS), the European Association of Nuclear Medicine (EANM), the Endocrine Society, the Society of Surgical Oncology, the National Comprehensive Cancer Network (NCCN), the American College of Physicians (ACP), the American Gastroenterological Association (AGA), and the World Conference on Interventional Oncology (WCIO) assembled under the auspices of an autonomous workgroup to develop the following AUC.
Details
- Title: Subtitle
- Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
- Creators
- Thomas A Hope - American College of Radiology, Reston, VirginiaEmily K Bergsland - North American Neuroendocrine Tumor Society, Albany, New YorkMurat Fani Bozkurt - European Association of Nuclear Medicine, Vienna, AustriaMichael Graham - Society of Nuclear Medicine and Molecular Imaging, Reston, VirginiaAnthony P Heaney - Endocrine Society, Washington, DCKen Herrmann - European Association of Nuclear Medicine, Vienna, AustriaJames R Howe - Society of Surgical Oncology, Rosemont, IllinoisMatthew H Kulke - National Comprehensive Cancer Network, Fort Washington, PennsylvaniaPamela L Kunz - National Comprehensive Cancer Network, Fort Washington, PennsylvaniaJosh Mailman - NorCal CarciNET, Ripon, CaliforniaLawrence May - American College of Physicians, Washington, DCDavid C Metz - American Gastroenterological Association, Bethesda, Maryland; andCorina Millo - Society of Nuclear Medicine and Molecular Imaging, Reston, VirginiaSue O'Dorisio - North American Neuroendocrine Tumor Society, Albany, New YorkDiane L Reidy-Lagunes - North American Neuroendocrine Tumor Society, Albany, New YorkMichael C Soulen - Society of Interventional Oncology, Washington, DCJonathan R Strosberg - North American Neuroendocrine Tumor Society, Albany, New York
- Resource Type
- Journal article
- Publication Details
- The Journal of nuclear medicine (1978), Vol.59(1), pp.66-74
- Publisher
- United States
- DOI
- 10.2967/jnumed.117.202275
- PMID
- 29025982
- PMCID
- PMC6910630
- ISSN
- 0161-5505
- eISSN
- 1535-5667
- Grant note
- P30 CA086862 / NCI NIH HHS P50 CA174521 / NCI NIH HHS
- Language
- English
- Date published
- 01/2018
- Academic Unit
- Radiology; Stead Family Department of Pediatrics; Surgery; Radiation Oncology
- Record Identifier
- 9984047787502771
Metrics
23 Record Views